Paris, France — Cellectis (Alternext: ALCLS.PA), a leader in the

development of adoptive immunotherapies based on engineered allogeneic CART cells

(UCART) announces today the sale of its subsidiary Cellectis AB to the Japanese

Company Takara Bio Inc.

This operation, which will be realized in the coming weeks subject to the completion of

certain usual conditions, is for Cellectis the extension to its strategic therapeutic focus.

The Company now concentrates its activities in the field of oncology through the

development of Chimeric Antigen Receptor T-cell (CAR-T) immunotherapy products

generated through its allogeneic CAR-T platform, both on its own as well as in

partnership with Servier and Pfizer.

Cellectis AB is a biotechnology company focused on applications of human embryonic

stem cell (hES) based products and technologies for the Industry and the research

community.

The quick downturn of the market had led Cellectis SA to restructure in 2013 its heavily

loss-making “Tools and Services” Business Unit. The sale of Cellectis AB is the last step

of the reorganization of this Business Unit which in 2013 recorded an operating loss of 14

million euros before booking of extraordinary depreciation and of the costs related to the

company downsizing.

The financials terms of the transaction have not been disclosed. It will lead to a loss of

about € 5 million in 2014 Cellectis’ books.

About Cellectis

Cellectis is a biopharmaceutical company focused on oncology. The company’s mission

is to develop a novel generation of therapies based on engineered T-cells to treat cancer.

Cellectis capitalizes on its 14 years of expertise in genome engineering, based on

TALEN™, meganucleases and the state-of-the-art electroporation technology Pulse

Agile, to create a new generation of cancer immunotherapy for treating leukemias and

solid tumors. Cellectis’ adoptive cancer immunotherapy for chronic and acute leukemias

is based on the first allogeneic T-cell chimeric antigen receptor (CAR) technology. CAR

technologies are designed to target surface antigens expressed on cells. These

treatments reduce toxicities associated with current chemotherapeutics and have the

potential for curative therapies. The Cellectis Group is focused on life sciences and uses

leading genome engineering technologies to build innovative products in various fields

and markets. Cellectis is listed on the NYSE Alternext market (ticker: ALCLS). To find out

more about us, visit our website: www.cellectis.com

For more information, please contact:

Cellectis

Philippe Valachs

Company Secretary

P.: +33 (0)1 81 69 16 00 – media@cellectis.comDisclaimer

This press release and the information contained herein do not constitute an offer to sell or

subscribe, or a solicitation of an offer to buy or subscribe for shares in Cellectis in any country. This press release contains forward-looking statements that relate to the Company’s objectives based on the current expectations and assumptions of the Company’s management only and involve

unforeseeable risk and uncertainties that could cause the Company to fail to achieve the objectives

expressed by the forward-looking statements.